Grifols Sa Adr Stock Today
| GRFS Stock | USD 8.10 0.12 1.50% |
PerformanceModest
| Odds Of DistressLow
|
Grifols SA is selling for under 8.10 as of the 19th of March 2025; that is 1.50% increase since the beginning of the trading day. The stock's lowest day price was 7.95. Grifols SA has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat modest performance during the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of May 2006 | Category Healthcare | Classification Health Care |
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company was founded in 1940 and is headquartered in Barcelona, Spain. Grifols SA operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. The company has 257.44 M outstanding shares of which 3.53 M shares are currently shorted by private and institutional investors with about 7.07 trading days to cover. More on Grifols SA ADR
Moving against Grifols Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Grifols Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | Jose Buenache | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Health Care, Biotechnology, Drug Manufacturers—General, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsGrifols SA can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Grifols SA's financial leverage. It provides some insight into what part of Grifols SA's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grifols SA ADR (GRFS) is traded on NASDAQ Exchange in USA. It is located in Avinguda de la Generalitat 152-158, Barcelona, Spain, 08174 and employs 23,833 people. Grifols SA is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 7.13 B. Grifols SA ADR conducts business under Biotechnology sector and is part of Health Care industry. The entity has 257.44 M outstanding shares of which 3.53 M shares are currently shorted by private and institutional investors with about 7.07 trading days to cover.
Grifols SA ADR currently holds about 549.09 M in cash with 208.28 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.4.
Check Grifols SA Probability Of Bankruptcy
Ownership AllocationGrifols SA ADR has a total of 257.44 Million outstanding shares. Over half of Grifols SA's outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Grifols Ownership Details
Grifols Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Hhg Plc | 2024-12-31 | 3 M | |
| Pictet Asset Manangement Sa | 2024-12-31 | 2.6 M | |
| Jpmorgan Chase & Co | 2024-12-31 | 2 M | |
| Norges Bank | 2024-12-31 | 1.9 M | |
| Blackrock Inc | 2024-12-31 | 1.9 M | |
| Ubs Group Ag | 2024-12-31 | 1.9 M | |
| Sei Investments Co | 2024-12-31 | 1.9 M | |
| New York State Common Retirement Fund | 2024-12-31 | 1.6 M | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.6 M | |
| Capital World Investors | 2024-12-31 | 21.1 M | |
| Brandes Investment Partners & Co | 2024-12-31 | 20.5 M |
Grifols SA Historical Income Statement
Grifols Stock Against Markets
Grifols SA Corporate Management
| Camille Alpi | Chief Officer | Profile | |
| Daniel Coit | Chief Officer | Profile | |
| Luis Garon | Managing Grifols | Profile | |
| Rahul Srinivasan | Chief Officer | Profile |
Additional Tools for Grifols Stock Analysis
When running Grifols SA's price analysis, check to measure Grifols SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Grifols SA is operating at the current time. Most of Grifols SA's value examination focuses on studying past and present price action to predict the probability of Grifols SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Grifols SA's price. Additionally, you may evaluate how the addition of Grifols SA to your portfolios can decrease your overall portfolio volatility.